Skip to main content

Advertisement

SpringerLink
Log in

TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

The present study analyzed the polymorphisms of apoptosis-related genes and their impact on the response to chemotherapy and survival of patients with advanced gastric cancer.

Patients and methods

Fifty-seven patients with advanced gastric cancer treated with paclitaxel and cisplatin combination chemotherapy were enrolled in the present study. The genomic DNA was extracted from paraffin-embedded tissue, and the single nucleotide polymorphisms (SNPs) of ten apoptosis-related genes [LTA, TP53, BCL2L11, BID, FASL, caspase 3, caspase 6, caspase 7, and caspase 9] determined using a polymerase chain reaction–restriction fragment length polymorphism assay.

Results

The Arg/Pro and Pro/Pro genotypes of TP53 codon 72 were significantly correlated with a lower response rate to the combination chemotherapy when compared to the Arg/Arg genotype (35.7 vs. 66.7%, P-value 0.019) in a logistic regression analysis. A multivariate survival analysis also showed that the time to progression for the patients with the Arg/Pro and Pro/Pro genotypes of TP53 codon 72 was worse than for the patients with the Arg/Arg genotype (Hazard ratio = 3.056, P-value = 0.047), whereas the overall survival was not significantly different.

Conclusion

The TP53 codon 72 SNP was found to be predictive of the response to chemotherapy and correlate with the time to progression in patients with advanced gastric cancer treated with paclitaxel and cisplatin chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Ransch M (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37–41

    Article  PubMed  CAS  Google Scholar 

  2. Pyrhonen S, Kuitunen T, Kouri M (1995) A randomized, phase III trial comparing fluorouracil, epidoxorubicin and methotrexate (FEMTX) with best supportive care in non-resectable gastric cancer. Br J Cancer 71:587–591

    PubMed  CAS  Google Scholar 

  3. Glimelius B, Hoffmann K, Haglund U, Nyron O, Sjoden PO (1994) Initial or delayed chemotherapy with best supportive in advanced gastric cancer. Ann Oncol 5:189–190

    PubMed  CAS  Google Scholar 

  4. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ, Kang WK, Suh CI, Bang YJ (1993) A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71:3813–3818

    Article  PubMed  CAS  Google Scholar 

  5. Vanhoefer U, Wagner T, Lutz M, Van Cutsem E, Nordlinger B, Reuse S, Baron B, Wilke H, Wils J (2001) Randomized phase II study of weekly 24-h infusion of high dose 5-FU ± folinic acid (HD-FU ± FA) versus HD-FU/FA/biweekly cisplatin in advanced gastric cancer. EORTC-trial 40953. Eur J Cancer 37:27

    Article  Google Scholar 

  6. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Hermann R, Honegger H, Cavalli F, Alberto P, Castighine M, Goldhirsch A (2000) Docetaxel (taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Ann Oncol 11:301–306

    Article  PubMed  CAS  Google Scholar 

  7. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, Sakata Y, Hyodo I (1999) Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17:319–323

    PubMed  CAS  Google Scholar 

  8. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF (1998) Phase II study of taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 4:269–274

    PubMed  CAS  Google Scholar 

  9. Bokemeyer C, Lampe CS, Clemens MR, Hartmann JT, Quietzsch D, Forkmann L, Kollmannsberger C, Kanz L (1997) A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer. Anticancer Drugs 8:396–399

    Article  PubMed  CAS  Google Scholar 

  10. Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, Baronius W, Hempd V, Uemens M, Kanz L, Bokemeyer C (2000) A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 83:458–462

    Article  PubMed  CAS  Google Scholar 

  11. Kim MK, Lee KH, Hyun MS, Do YR, Song HS, Lee WS, Park KU, Baek JH, Kim JG (2005) A multi-center, phase II clinical trial of Padexol (paclitaxel) and cisplatin for patients suffering with advanced gastric cancer. Cancer Res Treat 37:349–353

    Article  PubMed  Google Scholar 

  12. Kim JG, Sohn SK, Song HS, Kwon KY, Do YR, Lee KH, Hyun MS, Ryoo HM, Bae SH, Park KU, Baek JH, Lee WS, Chung JS, Cho GJ, Sohn CH, Jang JS, Chung HY, Yu W (2007) Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol 60:863–869

    Article  PubMed  CAS  Google Scholar 

  13. Ellis PA, Smith IE, McCarthy K, Detre S, Salter J, Dowsett M (1997) Preoperative chemotherapy induces apoptosis in early breast cancer. Lancet 349:849

    Article  PubMed  CAS  Google Scholar 

  14. Kerr JF, Winterford CM, Harmon BV (1994) Apoptosis. Its significance in cancer and cancer therapy. Cancer 73:2013–2026

    Article  PubMed  CAS  Google Scholar 

  15. Thomas M, Kalita A, Labrecque S, Pim D, Bank L, Matlashewski G (1999) Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19:1092–1100

    PubMed  CAS  Google Scholar 

  16. Dumont P, Leu JL, Della Pietra AC III, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptosis potential. Nat Genet 33:357–365

    Article  PubMed  CAS  Google Scholar 

  17. Rajaraman P, Wang SS, Rothman N, Brown MM, Black PM, Fine HA, Loeffler JS, Selker RG, Shapiro WR, Chanock SJ, Inskip PD (2007) polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol Biomarkers Prev 16:1655–1661

    Article  PubMed  CAS  Google Scholar 

  18. Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z, Lin B, Lu Y, Xie Y (2005) p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 11:7328–7333

    Article  PubMed  CAS  Google Scholar 

  19. Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, Goto H (2006) MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 24:4434–4440

    Article  PubMed  CAS  Google Scholar 

  20. Zhang ZW, Laurence NJ, Hollowood A, Newcomb P, Moorghen M, Gupta J, Feakins R, Farthing MJG, Alderson D, Holly J (2004) Prognostic value of TP53 codon 72 polymorphism in advanced gastric adenocarcinoma. Clin Cancer Res 10:131–135

    Article  PubMed  CAS  Google Scholar 

  21. Wang YC, Lee HS, Chen SK, Chang YY, Chen CY (1999) Prognostic significance of p53 codon 72 polymorphism in lung carcinoma. Eur J Cancer 35:226–230

    Article  PubMed  CAS  Google Scholar 

  22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan JS, Rubinstein L, Verweij J, Van Glabbeke M, Van Qosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  23. Pim D, Banks L (2004) p53 Polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108:196–199

    Article  PubMed  CAS  Google Scholar 

  24. Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, Attard M, Hiller L, Farrell PJ, Smith P, Lu X, Crook T (2004) Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23:3328–3337

    Article  PubMed  CAS  Google Scholar 

  25. Toyama T, Zhang Z, Nishio M, Hamaguchi M, Kondo N, Iwase H, Iwata H, Takahashi S, Yamashita H, Fujii Y (2007) Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res 9:R34

    Article  PubMed  CAS  Google Scholar 

  26. Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MMO, Oliver M, Skomedal H, Hainaut P, Trope CG, Abeler VM, Nesland JM, Borresen-Dale AL, Helland A (2004) Effect of the codon 72 polymorphism (c.215G > C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advance ovarian carcinoma. Hum Mutat 24:21–34

    Article  PubMed  CAS  Google Scholar 

  27. Santos AM, Sousa H, Portela C, Pereira D, Pinto D, Catarino R, Rodrigues C, Araujo AP, Lopes C, Medeiros R (2006) TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer. Biochem Biophys Res Commun 340:256–262

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology/Hematology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, South Korea

    Jong Gwang Kim, Sang Kyun Sohn & Yee Soo Chae

  2. Department of Hematooncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, South Korea

    Hong Suk Song, Ki-Young Kwon & Young Rok Do

  3. Department of Oncology/Hematology, Yeungnam University Hospital, Daegu, South Korea

    Min Kyoung Kim, Kyung Hee Lee & Myung Soo Hyun

  4. Department of Oncology/Hematology, Daegu Fatima Hospital, Daegu, South Korea

    Won Sik Lee

  5. Department of Oncology/Hematology, Inje University Hospital, Busan, South Korea

    Chang-Hak Sohn

  6. Department of Oncology/Hematology, Pusan National University Hospital, Pusan, South Korea

    Joo Seop Jung

  7. Department of Radiology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, South Korea

    Gab Chul Kim

  8. Department of General Surgery, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, South Korea

    Ho Young Chung & Wansik Yu

Authors
  1. Jong Gwang Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sang Kyun Sohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yee Soo Chae
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hong Suk Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ki-Young Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Young Rok Do
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Min Kyoung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kyung Hee Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Myung Soo Hyun
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Won Sik Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Chang-Hak Sohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Joo Seop Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Gab Chul Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Ho Young Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Wansik Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jong Gwang Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, J.G., Sohn, S.K., Chae, Y.S. et al. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. Cancer Chemother Pharmacol 64, 355–360 (2009). https://doi.org/10.1007/s00280-008-0879-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-008-0879-3

Keywords

Search

Navigation